Evaluation of the synergistic effect of coenzyme Q10 on the incidence of contrast nephropathy in patients with chronic kidney disease

Determining the synergistic effect of coenzyme Q10 on the incidence of nephropathy contrast in patients with chronic kidney disease: a randomized control trial

Clinical trial with a control group, with parallel groups, one blind (participants),randomized on 210 patients based on the list obtained from http://www.jerrydallal.com/random/randomize.htm

chronic kidney disease people referring to Dr.Heshmat Hospital, based on the random numbers,will be divided into two control and intervention groups.In the control group, they will receive the standard treatment such that ACE, ARB, Metformin, and NSAID drugs are stopped and NAC 1200mg.Isoosmolar contrast material and COQ10placebo supplement will be administered up to 48 hours after receiving it.in the intervention group, in addition to above cases, COQ10 will be prescribed .In both groups, at the beginning and on the third and fifth days, the baseline level of Bun-Cr-GFR and in addition the amount of urine volume will be measured on days 0 and 3.

Inclusion criteria: GFR less than -60 years of age over 18 years Exclusion criteria: performing emergency PCI or CAG before receiving standard treatment 24 hours before receiving contrast- presence of liver failure-presence of multiple myeloma disease and other plasma cell disorders- single kidney patients

Control group will receive standard treatment (ACE, ARB, metformin and NSAID drugs) will be stopped, NAC 1200mg twice a day and COQ10placebo supplement will be prescribed from 24 hours before receiving isosmolar contrast material to 48 hours after. In the intervention group, in addition to above cases, COQ10 (100 mg) will be prescribed daily from 24 hours before receiving the contrast material until 72 hours after it.

The incidence or non-incidence of contrast-induced nephropathy

The website http://www.jerrydallal.com/random/randomize.htm will be used for randomization. The randomization of this study will be by the blocked randomization method. Based on the list obtained from this website, each person will be randomly assigned to the control or intervention group using 6 random blocks with the number of 35 blocks in a ratio of 1:1. Using this method, each person is assigned one of the letters A or B to each group, and the list of codes obtained from this website will be provided to the project researchers for randomization, and each patient with chronic kidney disease with a GFR of less than 60 Those who meet the inclusion criteria will be entered the plan according to the assigned code. The steps to use this site will be as follows: we will enter the website through the http;//www.randomization.com link. Then, by entering the number of samples and the number of considered blocks, select the option on the left and the website will automatically generate the randomization list and people will be placed in the offending groups A and B, and the output file will be usable.

For blinding, placebos completely identical in terms of color, smell, shape and size to the COQ10 drug will be prepared for this study. The COQ10 drug used for the patients of this project will also be placed in unlabeled cans without any label (only it is obvious to the person giving the medicine) and will be available to the patients. For this purpose, the COQ10 supplement will be placed in capsules of a large and appropriate size, and in contrast to the placebo, the same-sized capsule will be filled with a suitable filler such as lactose by a pharmaceutics colleague present at the Faculty of Pharmacy and will be given to the control group; to be similar in appearance.